Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ranitidine is a small molecule drug that acts as a histamine H2 receptor antagonist, reducing the amount of acid produced by the stomach. It was widely used to treat and prevent ulcers in the stomach and intestines, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and conditions involving excessive gastric acid production. Ranitidine was available in oral (tablet, syrup) and injectable forms. In 2019–2020, ranitidine products were withdrawn from global markets due to contamination with N-nitrosodimethylamine (NDMA), a probable human carcinogen whose levels increase over time or at higher storage temperatures[2][6][8]. Common side effects included headache and gastrointestinal discomfort; rare but serious risks included liver injury, blood disorders, pneumonia risk increase, and masking of gastric cancer symptoms[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ranitidine.